Buy Target – $69.00 or better Sell Target – TradersPro Sell Signal Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in […]
Read MoreThese 3 stocks are the ones to buy now in the biotech space, according to Citi analyst Mohit Bansal.
Read MoreOne analyst says this small diagnostics firm has demonstrated its ability and is now a Buy.
Read MorePlus, the Fed is monitoring the coronavirus outbreak’s impact on the global economy, Victoria’s Secret is going private, and Domino’s delivered an earnings beat.
Read MorePlus, Citi says gold could hit $1,700 per ounce in the next 6 – 12 months, Tesla shares topped $930, and one speculative space stock has seen its trading volume explode.
Read MoreBuy Target – $9.25 or better Sell Target – TradersPro Sell Signal Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company’s lead product candidate is roluperidone, which is in Phase III clinical trial, a compound […]
Read MoreThis drugmaker has a promising treatment for the virus and one expert says the stock’s technical picture makes it a buy now.
Read MoreBuy Target – $17.50 or better Sell Target – TradersPro Sell Signal Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is Phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, […]
Read MorePlus, MGM Resorts’ chairman and CEO steps down as the casino operator withdraws its financial forecast for 2020, and Pepsi and Incyte report earnings.
Read MorePlus, the coronavirus finally has a name, Carnival Cruise Line said that the virus outbreak could dent full-year earnings, and Nissan is suing former Chairman Carlos Ghosn.
Read MorePlus, Fed Chairman Jerome Powell said the central bank is “closely monitoring” the effects of the coronavirus outbreak, and Under Armour shares are sinking after athletic apparel maker said it expects low-single digit sales growth this year.
Read MorePlus, Simon Property Group is acquiring Taubman Centers for $3.6 billion, and Eli Lilly shares are down after a failed trial for its Alzheimer’s drug candidate.
Read MoreBuy Target – $7.25 or better Sell Target – TradersPro Sell Signal NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; […]
Read MoreBuy Target – $5.15 or better Sell Target – TradersPro Sell Signal Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and […]
Read MorePlus, the coronavirus now has more than 20,000 confirmed cases globally, and Alphabet shares are lower after the Google parent reported lower-than-expected revenues.
Read More